Printer Friendly
The Free Library
23,396,934 articles and books


Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke.

TOKYO, November 7 /PRNewswire/ -- - Large, International REACH Registry Also Shows Many Patients With Atrial Fibrillation are Undertreated With Antiplatelet and Anticoagulant Therapies

A significant portion of patients with atherothrombosis also have atrial fibrillation (AF), greatly increasing their risk for cardiovascular death, heart attack and stroke, according to new findings from the large, international REACH registry published today in the American Heart Journal.(1) The findings also showed that standard treatments including anticoagulant and antiplatelet therapies are underused in AF patients.

The new findings from the REACH (REduction of Atherothrombosis for Continued Health) registry showed that AF was present in approximately 12% of patients who had atherothrombotic disease, which includes coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease (CVD). The findings also showed that, among patients with or at risk for atherothrombotic disease, the risk for death and non-fatal cardiovascular outcomes was greater for AF vs. non-AF patients, including more than twice as high for CV death (3.2% vs 1.4%; p<0.0001), 87% higher for death from all causes (4.3% vs. 2.3%, p<0.0001), 50% higher for non-fatal stroke (2.4% vs 1.6%, p<0.0001), and nearly 50% higher for the combined endpoint of CV death/heart attack/stroke and/or hospitalization for atherothrombotic events (17.9% vs 12.1%, p<0.0001). Despite these higher risks in AF patients, only a little more than half received anticoagulant therapy, only 60 percent received antiplatelet therapy, and less than one in five received both.

"We've known that AF is a major risk factor for ischemic stroke, but its prevalence and impact in the broader population of patients with atherothrombosis was previously unclear," said, lead author Shinya Goto, MD, PhD, FACC, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan. "Our findings help fill that gap, and show across all atherothrombotic disease categories, AF consistently increases the risk of death and non-fatal CV outcomes. For example, the combined endpoint of CV death, heart attack and stroke and/or hospitalization for atherothrombotic events was higher in AF patients no matter what form of atherothrombotic disease they initially had, and was highest in patients initially recruited with PAD. Further, our analysis underscores the need to determine the optimal management of AF patients with or at risk for atherothrombosis."

About the New REACH Analysis

The REACH registry is a large, contemporary, representative and geographically diverse cohort of stable outpatients with or at high risk of atherothrombosis.2,(3),(4) A total of 68,236 patients with either established atherothrombotic disease (CAD, PAD, or CVD, n=55,814) or at least three risk factors for atherothrombosis (n=12,422) were enrolled from 5,587 physician practices in 44 countries (in Europe, North and South America and Asia) in 2003-2004.

For this new analysis, the investigators identified REACH registry patients with or without AF, then compared those two groups in terms of risk factors, drug usage and one-year cardiovascular (CV) outcomes (CV death, heart attack and stroke).

AF status and one-year follow-up data were available for 63,589 patients. The prevalence of AF was 12.5%, 13.7%, 11.5%, and 6.2% among CAD, CVD, PAD, and risk factor-only patients, respectively; and 11.7% in patients with symptomatic atherothrombotic disease (CAD, CVD, or PAD together as one group). These prevalence rates are substantially higher than the estimated prevalence in the general population aged 40 years or more (2.3%) or 65 years or more (5.9%).(5)

Of the total 6,814 AF patients, 6.7% experienced CV death, non-fatal MI or non-fatal stroke within a year. Among the findings, the investigators showed that, after statistically adjusting for differences including age, sex, smoking, hypertension, diabetes, and hypercholesterolemia, the risks for death and non-fatal CV outcomes were worse in AF vs. non-AF patients:
 - CV death 129% greater (3.2% vs 1.4%; p<0.0001)
 - All-cause death 87% greater (4.3 vs 2.3, p<0.0001)
 - Non-fatal stroke 50% greater (2.4% vs 1.6%, p<0.0001)
 - The combined endpoint of CV death/heart attack/stroke and/or
 hospitalization for atherothrombotic event 48% greater (17.9% vs
 12.1%, respectively; p<0.0001), and highest in patients initially
 recruited
 with PAD (27.1%)





Only 58.4% of AF patients received antiplatelet agents, and only 53.1% received anticoagulant therapy. The rate of bleeding requiring hospitalization was higher in AF vs non-AF patients, respectively: 1.5% vs 0.8% (p<0.0001); the investigators speculated that this may have been due to the more frequent use of anticoagulants (53.1% vs 7.1%).

References

1. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-863.

2. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295(2):180-189.

3. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151(4):786 e1-10.

4. Steg PG, Bhatt DL, Wilson PWF, D'Agostino R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-1206.

5. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155(5):469-73.

CONTACT: For Further Information, please contact: Nick James, Chandler Chicco Agency, +44(0)7776-258-990, n.james@cca-uk.com; Dr. Deepak Bhatt, On Behalf of the REACH STEERING COMMITTEE, +1-857-203-6840/6841; Dr. Shinya Goto, Tokai University, +81-463-58-1211
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 2008
Words:974
Previous Article:Ritz Camera & Image Announces a Return to 1940's Pricing!
Next Article:University of Minnesota Study Says Students Eat More Whole Grains When Gradually Added to School Foods.



Related Articles
Clopidogrel Studied in One of the Largest Clinical Trial Programs in the Fight Against Atherothrombosis; Once complete, more than 100,000 patients...
Apnea linked to atrial fibrillation before age 65.
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial...
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial...
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation.
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation.
Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke.
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation.
AF AWARE Cardiology Groups Call for Greater Awareness and Better Education on Atrial Fibrillation.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters